Purchase Order HT940624P0092
Award Date
9/27/24
Potential Completion Date
9/26/27
Potential Value
$46K
Federal Agency
Defense Health Agency
Awardee
Cerus Corporation
Ultimate Awardee
Not listed
PSC Category
J065 - Maint/Repair/Rebuild Of Equipment- Medical, Dental, And Veterinary Equipment And Supplies
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Portsmouth, VA 23708, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price purchase order awarded by the Defense Health Agency (DHA) to Cerus Corporation, a biomedical products company specializing in blood safety technologies. The contract is for the service and maintenance of the Cerus INTERCEPT Illuminator, which is a key component of the company's proprietary INTERCEPT Blood System. The INTERCEPT system uses riboflavin and ultraviolet light to inactivate pathogens in blood components, including platelets, plasma, and red blood cells,...
This is a firm fixed-price purchase order contract awarded by the National Institutes of Health (NIH) Clinical Center to Cerus Corporation, a biomedical products company specializing in blood safety technologies and pathogen reduction systems. The contract, valued at $14,924.64, is for the provision of INTERCEPT Blood System equipment, illuminator maintenance services, and specialized pathogen reduction technology products. The contract has a performance period ending on June 7, 2025. Cerus...
This firm fixed-price purchase order contract was awarded by the Defense Health Agency (DHA) to Cerus Corporation, a biomedical products company specializing in blood safety technologies and pathogen reduction systems. The $369,384 contract is for the provision of Cerus' proprietary INTERCEPT Blood System, which uses riboflavin and ultraviolet light to inactivate pathogens in blood components, including platelets and plasma. This pathogen reduction technology plays a critical role in reducing...
This is a firm fixed-price purchase order contract awarded by the Defense Health Agency (DHA) to Cerus Corporation, a biomedical products company specializing in blood safety technologies and pathogen reduction systems. The contract, valued at $214,560.00, is for the delivery of INT2540B DROP SHIPMENT FOR PLATELET PROCESSING. This contract has no set-aside designation. Cerus Corporation is the prime contractor and there are no major subcontractors identified. The contract supports medical...
This is a firm fixed-price purchase order contract awarded by the National Institutes of Health (NIH) Clinical Center to Cerus Corporation, a biomedical products company specializing in blood safety technologies. The contract is for a Preventative Maintenance Agreement for the INTERCEPT Blood System Illuminators, with a period of performance from July 15, 2025, to July 14, 2026, and a ceiling value of $15,372.00. The contract does not have a set-aside designation. Cerus Corporation is the...
This is a firm fixed price purchase order contract awarded by the Defense Health Agency to Cerus Corporation, a biomedical products company that manufactures the INTERCEPT Blood System technology for pathogen reduction in blood components. The contract is for the DROP SHIPMENT OF INTERCEPT DUAL, with a potential value of $66,624.00 and a completion date of January 1, 2024. Cerus Corporation, the prime contractor, is a for-profit manufacturer that has received over 20 federal contract awards from...
The Defense Health Agency awarded a Firm Fixed Price, $186,048.00 purchase order contract to Cerus Corporation, a biomedical products manufacturer, for the drop shipment of medical supplies. The contract is sole source and not set aside. The supplies include the INTERCEPT Blood System technology, which uses riboflavin and UV light to inactivate pathogens in blood platelets and plasma. Cerus has received over 20 federal contract awards since 2002 from agencies such as the Department of Defense,...
This is a firm fixed-price purchase order contract awarded by the Defense Health Agency (DHA) to Cerus Corporation, a biomedical company specializing in blood safety technologies and pathogen reduction systems. The contract is for the delivery of INTERCEPT Platelet Processing Sets, which are used to inactivate pathogens in blood platelets. The contract has a ceiling value of $295,760.00 and an ultimate completion date of January 31, 2022. Cerus Corporation has consistently secured sole-source...
The Defense Health Agency has awarded Cerus Corporation, a for-profit manufacturer of biomedical products, a $87,166.08 firm fixed price purchase order contract to provide the INTERCEPT Blood System for Platelets. This pathogen reduction technology uses riboflavin and UV light to inactivate viruses, bacteria, protozoa, and contaminating white blood cells in platelet components. The contract, which does not have a set-aside designation, will run through June 18, 2024. Cerus has received over 20...
The Defense Health Agency awarded Cerus Corporation, a biomedical products company, a firm-fixed-price purchase order contract worth $190,080.00 for the supply of INTERCEPT Platelet Processing Sets and INTERCEPT Platelet Processing Sets with Dual Storage Containers. The contract is a sole-source award due to the proprietary nature of Cerus Corporation's INTERCEPT Blood System technology, which uses riboflavin and ultraviolet light to inactivate pathogens in blood components. This pathogen...